Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 3
Opinion
Video
Standard Treatment Options for BCG-Unresponsive NMIBC
Author(s):
Key Takeaways
- Intravesical chemotherapy aims to reduce recurrence and progression but may have limited efficacy and potential side effects.
- PD-L1 inhibitors enhance immune response but can cause immune-related adverse events and have variable patient response.
Katie S. Murray, DO, reviews the standard treatment options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), including intravesical chemotherapy, PD-L1 inhibitors, and other immunotherapeutic agents while highlighting the limitations of these therapies, such as incomplete response rates and potential adverse effects.
Video Player is loading.
- Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
- What limitations do these options have?
Related Videos
Future Directions of BCG-Unresponsive NMIBC Management
Adoption of New Treatments for BCG-Unresponsive NMIBC
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Discussing Treatment Options for BCG-Unresponsive NMIBC
Related Content
